Sonoma Pharmaceuticals Inc., of Petaluma, Calif., said it is now compliant with the minimum bid price requirement for continued listing on Nasdaq and is no longer subject to delisting at this time. To achieve compliance, the company implemented a 1-for-9 reverse stock split last month.